SANTANDREA, GIACOMO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 1.707
NA - Nord America 1.554
EU - Europa 861
SA - Sud America 225
AF - Africa 83
Continente sconosciuto - Info sul continente non disponibili 34
OC - Oceania 11
Totale 4.475
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.482
CN - Cina 507
SG - Singapore 425
IT - Italia 350
HK - Hong Kong 188
BR - Brasile 171
VN - Vietnam 170
GB - Regno Unito 108
BD - Bangladesh 83
KR - Corea 82
DE - Germania 75
RU - Federazione Russa 63
SE - Svezia 56
IN - India 50
FR - Francia 42
ID - Indonesia 39
CA - Canada 34
EG - Egitto 34
FI - Finlandia 32
MX - Messico 27
NL - Olanda 27
AR - Argentina 25
PK - Pakistan 25
IQ - Iraq 24
IR - Iran 23
ZA - Sudafrica 19
PL - Polonia 17
TR - Turchia 14
LT - Lituania 13
UA - Ucraina 12
AU - Australia 11
JP - Giappone 11
PH - Filippine 11
CO - Colombia 10
EC - Ecuador 10
ES - Italia 10
IL - Israele 9
AE - Emirati Arabi Uniti 7
AT - Austria 7
BE - Belgio 7
CH - Svizzera 7
NG - Nigeria 7
SA - Arabia Saudita 7
IE - Irlanda 6
MA - Marocco 6
MY - Malesia 6
JO - Giordania 5
PT - Portogallo 5
BG - Bulgaria 4
DZ - Algeria 4
PY - Paraguay 4
RO - Romania 4
RS - Serbia 4
UZ - Uzbekistan 4
AM - Armenia 3
ET - Etiopia 3
JM - Giamaica 3
PA - Panama 3
SN - Senegal 3
BF - Burkina Faso 2
GR - Grecia 2
HR - Croazia 2
KE - Kenya 2
KW - Kuwait 2
KZ - Kazakistan 2
TW - Taiwan 2
UY - Uruguay 2
AL - Albania 1
AO - Angola 1
AZ - Azerbaigian 1
BB - Barbados 1
BH - Bahrain 1
BO - Bolivia 1
BY - Bielorussia 1
CI - Costa d'Avorio 1
CL - Cile 1
CR - Costa Rica 1
CZ - Repubblica Ceca 1
DK - Danimarca 1
DO - Repubblica Dominicana 1
EE - Estonia 1
HN - Honduras 1
KH - Cambogia 1
LA - Repubblica Popolare Democratica del Laos 1
LB - Libano 1
LV - Lettonia 1
MD - Moldavia 1
MK - Macedonia 1
OM - Oman 1
QA - Qatar 1
TH - Thailandia 1
TN - Tunisia 1
TT - Trinidad e Tobago 1
VE - Venezuela 1
Totale 4.441
Salva come PNG Salva come JPEG
Città #
Santa Clara 284
Ashburn 263
Singapore 262
Hefei 227
Hong Kong 176
San Jose 123
Seoul 69
Beijing 59
Council Bluffs 59
Ho Chi Minh City 59
London 56
New York 53
Los Angeles 50
Milan 38
Chandler 35
Hanoi 29
Rome 29
Chicago 27
Buffalo 26
The Dalles 26
Helsinki 25
Cairo 23
Jakarta 23
São Paulo 23
Shanghai 22
Fairfield 21
Bologna 20
Lauterbourg 20
Nyköping 20
Kent 16
Munich 16
Schiffdorf 16
Moscow 15
Orem 15
Warsaw 15
Dallas 14
Johannesburg 14
Naples 11
Salt Lake City 11
Amsterdam 10
Da Nang 10
Florence 10
Mexico City 10
Modena 10
Bari 9
Islamabad 9
Nuremberg 9
Tokyo 9
Brembate di Sopra 8
Denver 8
Houston 8
Montreal 8
Rio de Janeiro 8
Toronto 8
Turin 8
Wuhan 8
Atlanta 7
Baghdad 7
Cambridge 7
Catania 7
Guayaquil 7
Haiphong 7
Istanbul 7
Phoenix 7
Boston 6
Dhaka 6
Dublin 6
Giza 6
Portsmouth 6
Raleigh 6
Redondo Beach 6
Seattle 6
Amman 5
Ann Arbor 5
Antwerp 5
Bagno a Ripoli 5
Belo Horizonte 5
Bengaluru 5
Brooklyn 5
Campi Bisenzio 5
Charlotte 5
Kunming 5
Lagos 5
Lahore 5
Las Vegas 5
Manchester 5
Miami 5
Migliarino 5
Parma 5
Poplar 5
San Diego 5
Turku 5
Austin 4
Belgrade 4
Boardman 4
Bremen 4
Chennai 4
Düsseldorf 4
Erbil 4
Geneva 4
Totale 2.676
Salva come PNG Salva come JPEG
Nome #
Assessment of estrogen receptor low positive status in breast cancer: Implications for pathologists and oncologists 564
Spatial Distribution of Immune Cells Drives Resistance to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer 241
Clinical Review of Mucosal Melanoma: The 11-Year Experience of a Referral Center 238
What do we have to know about pd-l1 expression in prostate cancer? A systematic literature review. part 1: Focus on immunohistochemical results with discussion of pre-analytical and interpretation variables 230
How can we treat vulvar carcinoma in pregnancy? A systematic review of the literature 216
A prognostic model based on residual cancer burden and tumor-infiltrating lymphocytes on residual disease after neoadjuvant therapy in HER2+ breast cancer 198
Sinonasal NUT Carcinoma: Delayed Diagnosis Due to the COVID-19 Pandemic and a Review of the Literature 197
What do we have to know about PD-L1 expression in prostate cancer? A systematic literature review. part 4: Experimental treatments in pre-clinical studies (cell lines and mouse models) 191
What do we have to know about pd-l1 expression in prostate cancer? A systematic literature review. part 5: Epigenetic regulation of pd-l1 177
Biomarkers changes after neoadjuvant chemotherapy in breast cancer: A seven-year single institution experience 172
Patient derived organoids are an useful tool to investigate Hippo pathway involvement in lung cancer 168
PRAME expression in cellular neurothekeoma: A study of 11 cases 162
Clinically unquestionable but histologically deceptive melanomas in acral skin grafts: PRAME confirms its role 157
The long non-coding RNA TAZ-AS202 promotes lung cancer progression via regulation of the E2F1 transcription factor and activation of Ephrin signaling 156
What do we have to know about PD-L1 expression in prostate cancer? A systematic literature review. Part 3: PD-L1, intracellular signaling pathways and tumor microenvironment 154
What do we have to know about pd-l1 expression in prostate cancer? A systematic literature review. part 2: Clinic–pathologic correlations 145
PHD2 (EGLN1) is a novel therapeutic target in KRAS-mutated lung carcinoma 138
Implementing an organoid platform to assess efficacy of PHD inhibitors as anti-cancer agents 138
Digital spatial profiling for pathologists 136
LncRNA TAZ-AS202 promotes lung cancer progression through the regulation of the E2F1 transcription factor 128
Medullary Thyroid Carcinomas Classified According to the International Medullary Carcinoma Grading System and a Surveillance, Epidemiology, and End Results-Based Metastatic Risk Score: A Correlation With Genetic Profile and Angioinvasion 125
A Two-Step Protocol for Isolation and Maintenance of Lung Cancer Primary 3D Cultures 108
Harnessing the hypoxia pathway to set a new therapeutic strategy for KRAS-mutated lung adenocarcinoma 103
Characterization of EGLN1 as a pro-oncogenic factor and pharmacological target in lung cancer 88
null 83
Exploring EGLN1 as a therapeutic target for KRAS mutated lung cancer 62
Totale 4.475
Salva come PNG Salva come JPEG
Categoria #
all - tutte 17.624
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 17.624
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202267 11 18 0 0 2 6 3 8 2 2 8 7
2022/2023129 9 12 6 5 10 14 2 15 12 13 14 17
2023/2024442 17 17 30 40 53 40 61 42 18 48 38 38
2024/20251.233 18 41 45 100 215 175 115 65 147 53 118 141
2025/20262.517 221 157 221 295 332 94 291 113 271 215 209 98
2026/202777 77 0 0 0 0 0 0 0 0 0 0 0
Totale 4.475